Significant Stagnancy in the Search and Use of New Antiarrhythmic Agents With Some Recent Beams of Hope
- 22 August 2025
- journal article
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 23 (2) , 1-15
Abstract
Over the last few decades, there has been noteworthy long-lasting stagnancy in the field of antiarrhythmic drugs (AAD), with the development of novel AAD notably declining over the years. Although ablation therapy has dominated, there remains an unmet need for effective and safe antiarrhythmic therapy in those choosing a conservative approach and those failing the ablation procedure( s). Also, in patients with life-threatening ventricular arrhythmias, in the era of the implantable cardioverter defibrillator dominance, many patients require effective and safe AAD therapy to mitigate the recurrence of arrhythmias and the delivery of painful and unpleasant device shocks. The repurposing and reformulation of current drugs in circulation for novel therapeutic uses may provide new avenues for developing antiarrhythmic treatments that can assist in curtailing cardiac arrhythmia- associated morbidity and mortality, and ameliorate the quality of life for millions of patients. Stressful factors may lead to endothelial dysfunction and a surge in blood pressure, contributing to the emergence of cardiac arrhythmogenic effects, including myocardial fibrosis and remodeling of structural, ion channels, and connexin 43 channels, with consequent dysfunction. Agents influencing this latter protein may have cardioprotective and potentially antiarrhythmic effects. In this review of new antiarrhythmic agents, the advantages of sodium-glucose co-transporter inhibitors, and also those of pirfenidone, ranolazine, sotatercept, mirabegron, nintedanib, and melatonin are discussed. Some of these agents have been approved for other indications and repurposed for use in managing arrhythmias. Finding novel antiarrhythmic therapeutic approaches may be challenging for further research.Keywords
This publication has 129 references indexed in Scilit:
- 26‐Week Repeated‐Dose Toxicity Study of a Novel Antiarrhythmic Drug Sulcardine Sulfate in Sprague–Dawley RatsJournal of Applied Toxicology, 2025
- Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in JapanAdvances in Therapy, 2024
- Recent Advances in Antiarrhythmic Drug TherapyDrugs, 2023
- Cardiovascular Toxicities Associated with Tyrosine Kinase InhibitorsCurrent Cardiology Reports, 2023
- β3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Associated with Heart Failure (SPHERE-HF): A Double Blind, Placebo-Controlled, Randomized Clinical TrialEuropean Journal of Heart Failure, 2022
- The Oral Ca/Calmodulin-Dependent Kinase II inhibitor RA608 Improves Contractile Function and Prevents Arrhythmias in Heart FailureESC Heart Failure, 2020
- Reduction of SR Ca2+ leak and arrhythmogenic cellular correlates by SMP-114, a novel CaMKII inhibitor with oral bioavailabilityBasic Research in Cardiology, 2017
- Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/BenefitDrug Safety, 2015
- Combined Cardiac Resynchronization and Implantable Cardioversion Defibrillation in Advanced Chronic Heart FailureJAMA, 2003
- Atypical Pulmonary and Neurologic Complications of Amiodarone in the Same PatientArchives of internal medicine (1960), 1987